POSC108 Estimated Hospitalization-Related Costs with Oral Azacitidine (ORAL-AZA) vs. Placebo for Remission Maintenance in Patients with Acute Myeloid Leukemia (AML) in Sweden and Norway
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.513
https://www.valueinhealthjournal.com/article/S1098-3015(21)02308-1/fulltext
Title :
POSC108 Estimated Hospitalization-Related Costs with Oral Azacitidine (ORAL-AZA) vs. Placebo for Remission Maintenance in Patients with Acute Myeloid Leukemia (AML) in Sweden and Norway
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02308-1&doi=10.1016/j.jval.2021.11.513
First page :
Section Title :
Open access? :
No
Section Order :
10051